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ABSTRACT Novelpandemicinﬂuenzavirusesenterthehumanpopulationwithsomeregularityandcancausediseasethatisse-
vereandwidespread.Theemergenceofnovelviruses,historically,hasoftenbeencoupledwiththedisappearanceofexistingsea-
sonalvirusstrains.Here,weproposethattheeliminationofseasonalstrainsduringviruspandemicsisaprocessmediated,at
thepopulationlevel,byhumoralimmunity.Speciﬁcally,wesuggestthatinfectionwithanovelvirusstrain,inpeoplepreviously
exposedtoinﬂuenzaviruses,canelicitamemoryBcellresponseagainstconservedhemagglutininstalkepitopesand/orneur-
aminidaseepitopes.Theanti-stalkand/oranti-neuraminidaseantibodiesthenacttodiminishtheclinicalseverityofdisease
causedbynovelinﬂuenzavirusesandtoeliminateseasonalvirusstrains.
EMERGENCE AND EXTINCTION OF INFLUENZA VIRUS
SUBTYPES IN THE HUMAN POPULATION SINCE 1918
Historically, the emergence of novel inﬂuenza virus subtypes in
the human population has been associated with worldwide epi-
demics (or pandemics). In recent history, the most devastating
exampleofanewsubtypeemerginginthehumanpopulationwas
the 1918 inﬂuenza virus, which expressed a subtype 1 hemagglu-
tinin protein (H1) and a subtype 1 neuraminidase protein (N1).
This H1N1 virus is estimated to have been responsible for 50 to
100milliondeathsoveraveryshortperiodoftime.H1N1variants
then circulated for 39 years before being replaced by an H2N2
virus (H2 subtype and N2 subtype) in 1957. The H2N2 virus was
prevalent for only 11 years until 1968, when it was replaced by an
H3N2virus(H3subtypewithretainedN2subtype).Curiously,in
1977, an H1N1 virus, which was actually the 1950 strain, reap-
peared and stayed on in parallel with the H3N2 seasonal virus
until 2009. In April 2009, a novel pandemic H1N1 virus emerged
in Mexico and proceeded to spread around the world. During the
subsequent2009-2010and2010-2011winterseasons,mostofthe
seasonal H1N1 viruses seem to have been replaced by this pan-
demic H1N1 strain (Fig. 1A) (1).
WHAT CAUSES THE EMERGENCE OF NOVEL INFLUENZA A
VIRUS SUBTYPES?
Besides environmental climate, the following two independent
elements appear to determine the ability of a new virus strain to
takeholdinthepopulation:(i)factorspresentinthespeciﬁcvirus
that enable transmission between humans and robust replication
inhumantissuesand(ii)theimmunestatusofthecurrenthuman
population.
Intermsofthegenerationofnovelvirusstrains,itislikelythat
all pandemic viruses (including the 1918 virus) result from a re-
assortment event following the coinfection of a host with two or
more different inﬂuenza viruses. The genome of each inﬂuenza
virusismadeupofeightRNAsegments,andduringcoinfectionof
a single cell, the parental virus segments can mix, causing the
generation of new virus strains which may express novel combi-
nations of hemagglutinin and neuraminidase subtypes. It is a
complex stochastic event that results in the emergence of a suc-
cessfulvirusstrainfromallofthe254possiblegenecombinations
thatcanoccurduringreassortmentofanytwoparentviruses.The
production of a new human strain by reassortment is also limited
by the host species in which the mixing event occurs. Thus, the
emergence of a reassortant virus that can cause pandemic human
diseaseisarareevent,andthespeciﬁcpropertiesofsuchavirusare
difﬁcult to predict.
Seasonal inﬂuenza virus strains are continually changing in
responsetotheexistingherdimmunityinthehumanpopulation.
This phenomenon, called antigenic drift, results in structural
changes within the globular head of the hemagglutinin protein,
while the hemagglutinin stalks are largely conserved within each
of the following two phylogenetic groups: the group 1 subtype
(e.g., H1 and H2) and the group 2 subtype (e.g., H3) (Fig. 2). The
immune status of any population against inﬂuenza viruses is
largelydeﬁnedbythepresenceorabsenceofneutralizingantibod-
ies. Two basic types of neutralizing antibodies have been de-
scribed: the highly potent, virus-speciﬁc globular head antibodies
and the less potent, cross-reactive anti-stalk antibodies. The
broadly neutralizing stalk-speciﬁc antibodies have been only re-
cently described, and it is not clear what role they play in the
protection of humans from inﬂuenza viruses. We propose that
broadly neutralizing anti-stalk antibodies serve to diminish the
clinical severity of inﬂuenza disease and, importantly, that they
can act in the elimination of seasonal virus strains during inﬂu-
enza pandemics. We further propose that antibodies against a
second surface glycoprotein, viral neuraminidase, can also lessen
the burden of inﬂuenza disease and act in the elimination of old
seasonal strains. Neuraminidase-speciﬁc antibodies do not pre-
vent virus infection; however, studies have demonstrated that
neuraminidase-speciﬁc antibodies are generated during virus in-
fection and that these speciﬁcities can mediate protection against
disease (2–4).
When a new pandemic strain enters the human population, it
predominantly induces an immune response against the hemag-
glutinin protein, but the viral neuraminidase is also an immuno-
genic protein. In each year following the disease pandemic, novel
escapemutationsoccur(mostlyinthehemagglutinin)inresponse
to the existing immunity present in the human population; many
of these mutations get ﬁxed in the viral genome and are likely to
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mortality rate during pandemic inﬂuenza seasons in the largely
naive age group of children under the age of 4 years. This age
group is less affected by herd immunity; thus, differential disease
rates between pandemic and typical seasons likely reﬂect true dif-
ferencesinthevirulenceofpandemicversusseasonalvirusstrains
(5–8).
WHAT MAY HAVE CAUSED THE DYING OUT OF THE H1N1
SUBTYPE STRAIN IN 1957?
In 1957, the H2N2 virus emerged, which
had a new hemagglutinin subtype (H2
versus H1). Although infection with an
H2viruswouldhaveinducedadistinctset
of antibody speciﬁcities, we hypothesize
that people who were previously infected
with H1N1 viruses would also have gen-
erated a memory response speciﬁc for
conserved group 1 stalk epitopes (9, 10).
While exposure to the antigenic head of
the H2 hemagglutinin would have caused
an immunological priming event, expo-
sure to the group 1 stalk would have lead
to a high-titer, class-switched, afﬁnity-
matured memory response (Fig. 2).
Members of the population who had ex-
perienced multiple seasonal exposures to
previously circulating H1 viruses would
have had memory cells capable of re-
sponding to conserved group 1 stalk
epitopespresentinthe1957pandemicvi-
rus; thus, this older population was
largely protected (or may have experi-
enced subclinical infection) in 1957—it
was the people aged 20 years and younger
who were seriously affected, with disease
ratesofover50%(11,12).Withthenovel
1957viruscausingasuddenboostinherd
immunity against group 1 viruses, and
because it was spreading within the sus-
ceptible population at rates much higher
than the existing seasonal H1 strain, the
older H1 virus was quickly extinguished.
Thus, we suggest that the induction of
cross-neutralizing antibodies directed
against the stalk of the H1 hemagglutinin
followinginfectionwiththerelatedgroup
1virus(H2N2)playedasigniﬁcantrolein
the protection of older segments of the
population from disease in 1957 and in
the elimination of the existing seasonal
H1N1 virus (Fig. 1A and B).
HOW DID THE H3N2 VIRUS
SUCCESSFULLY ELIMINATE THE H2N2
VIRUS IN 1968?
TheH3N2virusexpressedagroup2hem-
agglutinin, so it was less likely to have in-
duced cross-reactive anti-hemagglutinin
antibodies that mediated the elimination
of the existing H2N2 virus. However, in this case, the neuramini-
dasebetweentheH2N2andtheH3N2viruseswasthesame.Ithas
beensuggestedthatthelowrateofdiseaseinoldersegmentsofthe
population during the 1968 pandemic was a result of anti-N2
antibodies present due to prior exposure to H2N2 virus strains
(11). We postulate that the sudden generation of herd immunity
against the N2 protein in the younger population through infec-
tion with the H3N2 virus along with the existing immunity in the
older segments of the population caused the elimination of the
less-ﬁt H2N2 seasonal virus strain. The ability of neuraminidase-
FIG 1 Inﬂuenza A viruses circulating in the human population and induction of cross-protective
antibodiesbypandemicviruses.(A)H1N1indicatesviruswithhemagglutininsubtype1andneuramin-
idase subtype 1. H2N2 and H3N2 indicate viruses with hemagglutinin subtype 2 and neuraminidase
subtype2andhemagglutininsubtype3andneuraminidasesubtype2,respectively.pH1N1indicatesthe
novel swine origin virus ﬁrst isolated in 2009. (B) Antibody response in the human population, which
we propose to have contributed to the elimination of existing seasonal inﬂuenza virus strains. Gr1,
group 1 subtype; Gr2, group 2 subtype.
FIG 2 Representation of the major antigenic differences between hemagglutinin subtypes. Group 1
subtypes,suchasH1andH2,shareaconservedstalkdomain(darkgray);group2subtypes,suchasH3,
haveastalkdomainthatisstructurallydifferent(lightgray)fromthegroup1stalk.Theglobularheads
of the different hemagglutinin subtypes are structurally distinct (green/red/blue).
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tection in animal models against heterosubtypic virus strains that
share the same neuraminidase subtype has been established (2–4,
13–15). Thus, in 1968, an anamnestic immune response against
N2 likely decreased disease rates in the older population, but we
postulate that anti-N2 antibodies also had a dampening effect on
the seasonal H2N2 virus, resulting in its extinction.
WHY DID INFECTION WITH AN H1N1 VIRUS IN 1977 RESULT
IN COEXISTENCE WITH H3N2 VIRUSES?
In1977,a1950-likeH1N1straintookholdinthepopulation.We
hypothesizethattheH1N1virusstayedonbecauseboththehem-
agglutinin and the neuraminidase of the new strain were very dif-
ferent from those of the H3N2 virus and because a substantial
portion of the population had not been exposed to antigenically
similar viruses. The hemagglutinins of the two strains belong to
different phylogenetic groups, and preexisting immunity against
the 1977 strain did not exist in most of the (younger) population.
WHY DID PANDEMIC H1N1 REPLACE SEASONAL H1N1?
A new pandemic H1N1 strain (pH1N1) appeared in 2009. It con-
tained the hemagglutinin and the neuraminidase from inﬂuenza
viruses circulating in the pig population. The antigenic character
of the hemagglutinin was close to those of early H1N1 viruses but
was very different from those of the circulating seasonal H1N1
viruses. Some of the population may have been protected by ex-
istingcross-neutralizingantibodies,particularlyolderindividuals
whowereexposedtoearlystrainssimilartothepH1N1virus(16).
Recentdatasuggestthatbroadlyneutralizingantibodiesmayhave
signiﬁcantly diminished disease severity while not protecting
againstinfectionwiththe2009pandemicvirus(17).Althoughthe
H1N1 hemagglutinins were sufﬁciently different to allow the
seeding of the new pH1 strain within susceptible populations, the
pH1 stalk region (which is highly conserved in the two H1N1
strains) induced a sudden large-scale cross-protective immune
response (17) that likely contributed to the elimination of the
seasonal H1N1 virus over the 2009-2010 and 2010-2011 seasons.
Antibodies against the highly similar neuraminidase proteins in
the seasonal and pandemic H1N1 strains may have further re-
duced the spread of the less virulent seasonal H1N1 strain.
WHAT CAN WE PREDICT FOR THE FUTURE?
Based on the hypothesis that related viruses induce cross-
protective immunity via their conserved hemagglutinin stalks
and/ortheirconservedneuraminidases,itislikelythatpH1N1will
completelydisplacetheseasonalH1N1viruses.Thus,thepH1N1,
H3N2, and B viruses will continue to circulate until a new pan-
demic inﬂuenza virus strain emerges. If a new pandemic strain
induces cross-reactive stalk antibodies, it will likely eliminate one
orbothofthecirculatingAstrains—theemergenceofapandemic
H2N2 virus strain would likely result in the elimination of both
seasonal strains due to a sudden boost in titer, at a population
level, of both anti-group 1 hemagglutinin and anti-N2 protective
antibodies. If, however, the new pandemic strain is sufﬁciently
different in both its hemagglutinin and neuraminidase, it may
actually cocirculate with the present strains without causing the
H3N2 or pH1N1 strains to die out. Which particular hemaggluti-
nin subtype such a new pandemic strain will possess and when
such an event will occur cannot be predicted.
Insummary,thepresentdiscussionsuggeststhattheinduction
of a large-scale humoral immune response against conserved
hemagglutinin stalk epitopes and/or against the neuraminidase
protein results in the clearance of old seasonal inﬂuenza virus
strains. If the newly introduced pandemic strain has a very diver-
gent hemagglutinin (belonging to a different hemagglutinin
group) and does not share the neuraminidase subtype, it is likely
to coexist with the prepandemic seasonal inﬂuenza virus strain.
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